The Company will also join Biotech Showcase 2023, which will be taking place in parallel to the
Details of the events are as follows:
Event:
Date:
Event: https://www.jpmorgan.com/solutions/cib/insights/health-care-conference
Registration through BIO One-on-One Partnering system (BIO @ JPM): https://www.bio.org/events/bio-partnering-jpm
Event: Biotech Showcase 2023
Date:
During the event period, the core members of the Company will hold one-on-one meetings with registered investors and pharmaceutical companies to introduce
At
About
The Company's main pipeline assets include olinvacimab, the lead asset in clinical stage, and IND-ready preclinical assets with first-in-class potential such as PMC-309 and PMC-403.
Olinvacimab, the Company's lead asset, is undergoing a Phase II trial in combination with MSD's pembrolizumab for mTNBC patients in
PMC-309, a novel anti-VISTA-antagonizing IgG in pan pH, is an immune checkpoint regulator that targets MDSC (myeloid derived suppressor cells) and M2 macrophages which play pivotal role in maintaining immunosuppressive TME (Tumor Microenvironment). The Company plans to submit Clinical Trial Application for a Phase I study in early 2023.
PMC-403 is a novel TIE2-activating antibody that stabilizes dysfunctional leaky disorganized pathological vessels and can be used for vascular-related eye disease, including wet AMD (Age-related Macular Degeneration). The Company expects to initiate a Phase I ophthalmology clinical trial in early 2023.
One of other early-stage assets, PMC-005, is an anti-EGFRviii IgG that only binds to EGFRviii expressed on cancer cells and can be applied to various modalities including CAR-T, CAR-NK, CAR-Macrophage, T cell/NK cell engager, and Radio-Immunotherapy
Contact:
Tel: +82 70 4279 5100
Email: bd@pharmabcine.com
(C) 2022 Electronic News Publishing, source